title: Hepatic grafts from live donors: donor morbidity for 470 cases of live donation.
abstract: Living donor-morbidity was evaluated in 470 consecutive cases of living donor liver transplantation carried out from June 1990 to May 1999 at Kyoto University. Grafting was categorized into 4 groups according to the resection lines; left lateral segmentectomy (S2 + 3, n = 282, R1), extended left lateral segmentectomy without middle hepatic vein (MHV) (S2 + 3 + part4, n = 45, R2), left lobectomy with MHV (S2 + 3 + 4, n = 99, R3) and right lobectomy without MHV (S5 + 6 + 7 + 8, n = 43, R4). Intraoperative blood loss and operation duration were less for left lateral segmentectomy, but no significant difference was observed between left lobectomy and right lobectomy. The length of postoperative hospital stays was comparable among all groups except for the group with right lobe grafting. The AST values at the peak and at POD 7 were significantly elevated for right lobectomy, but the AST value normalized within one month in the majority of the cases. The close follow-up of donors with more than 1,000 ml intraoperative bleeding, and of those donors who stayed in hospital for more than 30 days, the close follow-up, furthermore, of those donors with AST values higher than 100 IU/ L AST after one month, revealed complete recovery. Biliary leakage was the most common and annoying complication after donor operations, especially in for right lobe grafting, but all donors recovered completely with conservative or minimal invasive therapy. The two cases of re-operation due to adhesive mechanical ileus we encountered were resolved completely. Finally, no donor-operation related death was noted. In conclusion, the morbidity of living donors is low or minimal even for right lobectomy, the most extended procedure, and complete recovery can be expected in all cases.
authors.affiliation: Kyoto University Hospital, Kyoto University, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Fujita
authors.forename: I D
authors.initials: ID
authors.lastname: Kim
authors.forename: K
authors.initials: K
authors.lastname: Uryuhara
authors.forename: K
authors.initials: K
authors.lastname: Asonuma
authors.forename: H
authors.initials: H
authors.lastname: Egawa
authors.forename: T
authors.initials: T
authors.lastname: Kiuchi
authors.forename: M
authors.initials: M
authors.lastname: Hayashi
authors.forename: S
authors.initials: S
authors.lastname: Uemeto
authors.forename: Y
authors.initials: Y
authors.lastname: Inomata
authors.forename: K
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D001663:Bilirubin / Q000097:blood; D016063:Blood Loss, Surgical; D002648:Child; D005190:Family; D005260:Female; D006498:Hepatectomy / Q000009:adverse effects* / Q000379:methods; D006801:Humans; D007902:Length of Stay; D016031:Liver Transplantation / Q000706:statistics & numerical data*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009679:Nuclear Family; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology*; D012189:Retrospective Studies; D018454:Spouses; D020858:Tissue and Organ Harvesting / Q000009:adverse effects* / Q000379:methods
chemical_list: D001663:Bilirubin